OTCPK:MRNA +23% . CPSL +21% . PME +21% . CBAK +16% . BYD +15% . Top 10 Losers: INUV -19% . SSH -17% . ARTX -16% . FTEK -15% . HRT -15% . MY -12% . COSI -11% . CPGI -11% . MYGN -10% . XGTI -9% . Post your comment!
Myriad Genetics announced Tuesday that its motion for preliminary injunctive relief in its case against Ambry Genetics has been denied, which
CPST +12% . BLDP +11% . PLUG +9% . OPTT +8% . QTWW +8% . JCP +7% . PPHM +7% . NWBO +6% . NVAX +5% . [] +% . [] +% . [] +% . Losers: FTEK -19% . AEO -5% . MYGN -5% . TESO -5% . Post your comment!
March 11 (Reuters) - Myriad Genetics Inc said a U.S. court denied its motion to temporarily stop rival Ambry Genetics Corp from selling products similar to Myriad's gene-based cancer test, the latest setback for the diagnostics company.
Shares are also under pressure in response to yesterday's US court ruling denying Myriad's ( MYGN ) motion for a preliminary injunction again Ambry Genetics. The company is trying to prevent its rival from selling a cancer test
Shares of Myriad Genetics ( MYGN ) are poised for an opening gap down on probable profit-taking after its recent 96% run-up from the December 30 low of $20
March 11 (Reuters) - Diagnostics company Myriad Genetics Inc said a U.S. court denied a motion that would have stopped rival Ambry Genetics Corp from selling a similar version of Myriad's cancer test.
potentially generate substantial returns for shareholders uncorrelated with the market. Background on Myrexis: On 06/30/09, Myriad Genetics spun-off its cancer research and drug development business to shareholders. After spending two and a Complete Story
Myriad Genetics ( MYGN ) jumped nearly 11.5% today on news its Prolaris genetic testing method proved effective in predicting which men would see a
By Alan Kotok : Myriad Genetics ( MYGN ), a developer of medical tests from molecular information ..... this type of information vital for diagnosis and treatments. Myriad Genetics , based in Salt Lake City, develops tests for hereditary risks